Short-term Results of a Pulsed Therapy with Hydrocortisone Eye Drops to Treat Moderate to Severe Dry Eye in Primary Sjögren Syndrome Patients

Overview

Journal Graefes Arch Clin Exp Ophthalmol

Specialty Ophthalmology

Date 2022 Oct 3

PMID 36192456

Authors

Martina Menchini

Francesco Sartini

Michele Figus

Giovanna Gabbriellini

Affiliations

Soon will be listed here.

Abstract

Background: We investigated the safety and efficacy of short-term treatment with topical low-dose hydrocortisone sodium phosphate 0.335% (PFH) in patients with moderate to severe primary Sjögren syndrome (SS)-related dry eye disease (DED).

Methods: A retrospective single-centre interventional study. All patients received PFH for 6 days with a pulsed posology: three times daily for 2 days, twice daily for 2 days, and once daily for 2 days. This scheme was repeated for 3 consecutive months and then alternated for 3 months. Data were collected at baseline, 3 months, and 6 months of follow-up.

Results: A total of 40 SS patients were enrolled. Conjunctival hyperaemia and corneal-conjunctival stain significantly improved (p < 0.001). Ocular Surface Disease Index score reduced significantly between baseline and 3 months and between baseline and 6 months (p < 0.001). The tear film osmolarity lowered significantly in each eye from baseline to 3 months and from baseline to 6 months (p = 0.002 and p = 0.037, respectively). Comparing results at 3 and 6 months, the Ocular Surface Disease Index score (p = 1.000), the frequency of lacrimal substitutes installation (p = 0.632), and tear film osmolarity (right eye p = 0.518, left eye p = 1.000) did not change significantly. Intraocular pressure did not change during the study period.

Conclusion: PFH eye drops with a pulsed posology improve signs and symptoms, not affecting the intraocular pressure in SS-related DED. Therefore, this pulsed treatment is safe and efficacious.

Citing Articles

Role of Chinese Medicine Monomers in Dry Eye Disease: Breaking the Vicious Cycle of Inflammation.

Hu Z, Chen X, Hu Q, Zou M, Liu Z Pharmacol Res Perspect. 2025; 13(2):e70077.

PMID: 39979080 PMC: 11842162. DOI: 10.1002/prp2.70077.

"Dirty Dry Eye"- A waste volume analysis from topical therapy in keratoconjunctivitis sicca.

Schilcher A, Roth M, Steindor F, Helweh R, Geerling G Graefes Arch Clin Exp Ophthalmol. 2024; 262(9):2917-2924.

PMID: 38520515 PMC: 11377519. DOI: 10.1007/s00417-024-06431-y.

Hormones and dry eye disease.

Gorimanipalli B, Khamar P, Sethu S, Shetty R Indian J Ophthalmol. 2023; 71(4):1276-1284.

PMID: 37026259 PMC: 10276676. DOI: 10.4103/IJO.IJO_2887_22.

References

Jonsson R, Vogelsang P, Volchenkov R, Espinosa A, Wahren-Herlenius M, Appel S . The complexity of Sjögren's syndrome: novel aspects on pathogenesis. Immunol Lett. 2011; 141(1):1-9. DOI: 10.1016/j.imlet.2011.06.007. View

Akpek E, Bunya V, Saldanha I . Sjögren's Syndrome: More Than Just Dry Eye. Cornea. 2019; 38(5):658-661. PMC: 6482458. DOI: 10.1097/ICO.0000000000001865. View

Segal B, Bowman S, Fox P, Vivino F, Murukutla N, Brodscholl J . Primary Sjögren's Syndrome: health experiences and predictors of health quality among patients in the United States. Health Qual Life Outcomes. 2009; 7:46. PMC: 2693523. DOI: 10.1186/1477-7525-7-46. View

Foulks G, Forstot S, Donshik P, Forstot J, Goldstein M, Lemp M . Clinical guidelines for management of dry eye associated with Sjögren disease. Ocul Surf. 2015; 13(2):118-32. DOI: 10.1016/j.jtos.2014.12.001. View

Adatia F, Michaeli-Cohen A, Naor J, Caffery B, Bookman A, Slomovic A . Correlation between corneal sensitivity, subjective dry eye symptoms and corneal staining in Sjögren's syndrome. Can J Ophthalmol. 2005; 39(7):767-71. DOI: 10.1016/s0008-4182(04)80071-1. View

Craig J, Nichols K, Akpek E, Caffery B, Dua H, Joo C . TFOS DEWS II Definition and Classification Report. Ocul Surf. 2017; 15(3):276-283. DOI: 10.1016/j.jtos.2017.05.008. View

Liu H, Begley C, Chen M, Bradley A, Bonanno J, McNamara N . A link between tear instability and hyperosmolarity in dry eye. Invest Ophthalmol Vis Sci. 2009; 50(8):3671-9. DOI: 10.1167/iovs.08-2689. View

Jones L, Downie L, Korb D, Benitez-Del-Castillo J, Dana R, Deng S . TFOS DEWS II Management and Therapy Report. Ocul Surf. 2017; 15(3):575-628. DOI: 10.1016/j.jtos.2017.05.006. View

Razeghinejad M, Katz L . Steroid-induced iatrogenic glaucoma. Ophthalmic Res. 2011; 47(2):66-80. DOI: 10.1159/000328630. View

10.

Kallab M, Szegedi S, Hommer N, Stegmann H, Kaya S, Werkmeister R . Topical Low Dose Preservative-Free Hydrocortisone Reduces Signs and Symptoms in Patients with Chronic Dry Eye: A Randomized Clinical Trial. Adv Ther. 2019; 37(1):329-341. DOI: 10.1007/s12325-019-01137-8. View

11.

Carnahan M, Goldstein D . Ocular complications of topical, peri-ocular, and systemic corticosteroids. Curr Opin Ophthalmol. 2001; 11(6):478-83. DOI: 10.1097/00055735-200012000-00016. View

12.

McGhee C, Dean S, Danesh-Meyer H . Locally administered ocular corticosteroids: benefits and risks. Drug Saf. 2002; 25(1):33-55. DOI: 10.2165/00002018-200225010-00004. View

13.

Sheppard J, Comstock T, Cavet M . Impact of the Topical Ophthalmic Corticosteroid Loteprednol Etabonate on Intraocular Pressure. Adv Ther. 2016; 33(4):532-52. PMC: 4846687. DOI: 10.1007/s12325-016-0315-8. View

14.

Vitali C, Bombardieri S, Jonsson R, Moutsopoulos H, Alexander E, Carsons S . Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis. 2002; 61(6):554-8. PMC: 1754137. DOI: 10.1136/ard.61.6.554. View

15.

Wolffsohn J, Arita R, Chalmers R, Djalilian A, Dogru M, Dumbleton K . TFOS DEWS II Diagnostic Methodology report. Ocul Surf. 2017; 15(3):539-574. DOI: 10.1016/j.jtos.2017.05.001. View

16.

Bron A, Evans V, Smith J . Grading of corneal and conjunctival staining in the context of other dry eye tests. Cornea. 2003; 22(7):640-50. DOI: 10.1097/00003226-200310000-00008. View

17.

Efron N . Grading scales for contact lens complications. Ophthalmic Physiol Opt. 1998; 18(2):182-6. DOI: 10.1016/s0275-5408(97)00066-5. View

18.

Pult H, Nichols J . A review of meibography. Optom Vis Sci. 2012; 89(5):E760-9. DOI: 10.1097/OPX.0b013e3182512ac1. View

19.

Schiffman R, Christianson M, Jacobsen G, Hirsch J, Reis B . Reliability and validity of the Ocular Surface Disease Index. Arch Ophthalmol. 2000; 118(5):615-21. DOI: 10.1001/archopht.118.5.615. View

20.

Avunduk A, Avunduk M, Varnell E, Kaufman H . The comparison of efficacies of topical corticosteroids and nonsteroidal anti-inflammatory drops on dry eye patients: a clinical and immunocytochemical study. Am J Ophthalmol. 2003; 136(4):593-602. DOI: 10.1016/s0002-9394(03)00326-x. View